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Enhanced body growth in uremic rats treated with IGF-I and growth
hormone in combination. The efficacy of seven days treatment with
IGF-I (1.7 mg/kg/day), growth hormone (GH) (2 mg/kg/day), IGF-
I+GH (1.7 mg/kg/day + 2 mg/kg/day) or vehicle, in promoting growth
was investigated in female Sprague-Dawley rats with 5/6 nephrectomies
(N = 8 per group). Treatment commenced after chronic renal failure
had been present for seven weeks. Significant increases in body weight
gain were found in all groups versus control, with IGF-I+GH causing
the greatest response, and increased body weight gains correlating with
increased nitrogen retention. GH treatment alone significantly stimu-
lated food intake. IGF-I+GH resulted in close to additive increases in
food conversion efficiency (18.8%, 21.5% and 39.6% increases with
IGF-I, GH and IGF-I+GH, respectively, over control levels) and
longitudinal bone growth (39%, 37% and 67% increases with IGF-I, GH
and IGF-I+GH, respectively, vs. control). Serum insulin and choles-
terol levels significantly decreased with IGF-I and IGF-I+GH treat-
ment. Creatinine clearance did not change, suggesting there were no
effects of treatment on kidney function. Although IGF-I at the doses
used did not result in a greater anabolic response than GH, IGF-I+GH
caused significantly enhanced growth while reducing serum insulin and
cholesterol levels.
Chronic renal failure is associated with significant growth
retardation in children. Factors contributing to this growth
impairment include metabolic acidosis, renal osteodystrophy,
anemia, and hormonal derangements [1]. Of particular impor-
tance to an increased knowledge of the pathogenesis of growth
retardation in uremia has been a better understanding of the
associated perturbations in the growth hormone/insulin-like
growth factor I axis.
Growth hormone (GH) has both direct and indirect effects to
enhance growth, the latter being mediated by insulin-like
growth factor-I (IGF-I) which is released from target tissues to
have endocrine, paracnne and autocrine actions [2]. Growth
retardation in chronic renal failure occurs despite normal to
high serum GH levels and normal serum levels of IGF-I [3].
However, there is evidence that IGF-I secretion rates are
substantially lower than normal in children with chronic renal
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failure [31. This occurs despite elevated GH levels, which would
normally be expected to increase IGF-I secretion, and suggests
a state of GH resistance. In addition to the reduced IGF-I
production, IGF-I bioactivity is attenuated in uremia [3]. Re-
duced IGF-I bioactivity may be due, at least in part, to an
increase in specific binding proteins for IGF (IGFBPs) in the
serum, as removal of excess IGFBPs from patient sera by
affinity chromatography results in increased IGF-I bioactivity
[3].
Following experiments demonstrating improved growth in
uremic rats treated with GH [4, 5], and with increased avail-
ability of recombinant human GH (rhGH), clinical trials of
rhGH treatment in children with chronic renal failure have been
undertaken around the world. However, since clinical usage is
still relatively recent, the long-term effects of GH treatment in
uremia are still to be determined. In children with chronic renal
failure hormonal and metabolic derangements such as insulin
resistance are present [1], and may be exacerbated by the
hyperinsulinemic effect of GH [6]. The outcome of GH treat-
ment on residual renal function must also be monitored, as
studies in transgenic mice expressing high levels of GH have
demonstrated progressive glomerulosclerosis [7]. In addition,
because uremia appears to be a GH resistant state it is possible
that, although GH administration can promote growth in ure-
mia, it may not be the most efficient means of treatment, since
GH stimulation of IGF-I secretion will still be impaired.
IGF-I treatment has previously been shown to improve
growth in rats with reduced renal mass [8] and could, by
circumventing the GH resistance of uremia, result in higher
growth rates than GH. Apart from improving growth, another
possible advantage of therapy with IGF-I is that it has some
metabolic effects opposed to those of GH. For example, IGF-I
causes hypoglycemia and reduced insulin secretion [9], in
contrast to the hyperinsulinemia and hyperglycemia of GH.
Combination therapy using IGF-I plus GH could thus result in
reduced metabolic perturbations in contrast to treatment with
either peptide individually. Even greater therapeutic potential
has been suggested by the recent report by Kupfer and co-
workers that a combination of IGF-I and GH has greater
anabolic effects than either IGF-I or GH alone [10]. In studies in
GH-deficient rats the combination of IGF-I and GH was also
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found to have additive effects on whole body growth (Clark,
Carisson and Cronin, unpublished studies).
The aim of this study was to compare the effects on growth of
seven days treatment with IGF-I and GH, alone and in combi-
nation, in a rat model of chronic renal failure and growth
retardation.
Methods
Peptides
Recombinant human IGF-I (rhIGF-I) and recombinant hu-
man GH (rhGH) were donated by Genentech, South San
Francisco, California.
Experimental animals
Before undertaking the study on the effects of IGF-I and/or
GH on growth in chronic renal failure, a reproducible model of
chronic renal impairment was characterized in a series of pilot
studies. Requirements for the model included a stable and
reproducible degree of renal failure, with significant growth
retardation. Weanling female Sprague-Dawley rats weighing 60
to 120 g (86.8 10.0 g, mean SD; N = 44) were anesthetized
using methohexitone sodium (45 mg/kg i.p.) and the right
kidney exteriorized through a flank incision, and decapsulated.
The upper and lower poles and lateral margins of the right
kidney were resected, avoiding penetration of the renal pelvis.
An average of 0.294 0.070 g kidney tissue per 100 g body wt
was removed by this method (mean SD). Hemostasis was
achieved using digital pressure and a sterile gauze swab. In the
sham operated animals the flank incision was made, and the
kidney exteriorized and decapsulated, then replaced in the
abdomen. Two days later the left kidney was removed through
a flank incision, sparing the adrenal gland, with the kidney of
the sham operated rats again being decapsulated only. Post-
surgical analgesia was provided by buprenorphine (0.01 to 0.05
mg/kg sc). The rats were housed in individual rat boxes with ad
libitum access to tap water and standard rat chow (minimum
protein 21%, 3175 kcallkg available energy, 2000 lU/kg vitamin
D3, 0.76% calcium and 0.46% available phosphate, Milling
Industries, Murray Bridge, South Australia) and a 12:12 light
and dark cycle. Animals were weighed daily for 50 days, with
weekly blood sampling from the tail vein between weeks two to
seven.
Experimental protocol
For the experiment itself, a total of 32 weanling female
Sprague-Dawley rats of 65 to 95 g body weight were used. Due
to limitations in the number of metabolism cages, the study was
completed in two stages of 19 and 13 rats, respectively. Surgery
was performed as described above, and blood collected at days
14 and 28 for assessment of renal failure by measurement of
serum urea and creatinine. Rats were held in individual rat
boxes and fed standard rat chow (as above). At 43 days after
surgery the rat chow diet was replaced with a casein based diet
(22% protein, free of 3-methyl histidine and creatinine). At 45
days post-surgery, rats were transferred to metabolism cages
for a four day acclimatization prior to commencement of the
treatment period. Daily 24-hour collections of urine and feces
were made, and daily food and water consumption measured
from the day before (48 days post-surgery) and for the subse-
quent seven days of the treatment period. Food conversion
efficiency was calculated as the weight gain per unit of food
intake over the seven-day treatment period, converted to a
percentage. The daily water balance was calculated as the water
intake (ml) minus the urine output (ml).
The commencement of the treatment period, at seven weeks
following the onset of renal failure, was designated as Day 0. On
this day the rats were randomly allocated into four groups of
eight each, and treated for seven days with either vehicle
(control group), IGF-I, GH, or a combination of IGF-I+GH.
Under halothane anesthesia, an osmotic minipump (Aizet
Model 2001; Alza, Palo Alto, California, USA) was inserted
subcutaneously on the dorsum of each rat for administration of
either rhIGF-I (420 ig/day), or vehicle (0.1 M acetic acid). At
the same time, daily subcutaneous injections of either rhGH
(500 pjg/day), or vehicle (sterile water), were commenced.
Thus, each rat had an osmotic minipump implanted and was
given daily injections. While the rats were still anesthetized
with deep muscle relaxation, the body length (snout to tail tip)
was measured using a ruler, and blood collected from the tail
vein for serum urea and creatinine measurement. Also at this
time the fluorochrome marker calcein was injected intraperito-
neally (10 mg/kg body wt) for estimation of longitudinal bone
growth over the week of treatment.
On Day 7 of treatment, following the daily 24-hour collections
the rats were anesthetized with methohexitone sodium (45
mg/kg i.p.) and exsanguinated. The remnant kidney was re-
moved and weighed, body length measured, and the right tibia
removed. Aliquots of serum were stored at —20°C until further
analysis. In addition, blood was collected from five normal
female Sprague-Dawley rats, and the serum stored frozen at
—20°C for normal serum biochemistry levels.
All procedures were undertaken with approval of the Animal
Ethics Committee of the Women's and Children's Hospital,
Adelaide.
Sample analyses
Concentrations of urea and creatinine in the serum and urine
were measured using Unikit assay kits for the COBAS BlO
system (Roche Diagnostica), and creatinine clearance calcu-
lated for days 0 and 7. For all other analyses of urine and feces,
pools were made of pre-treatment (Day —ito Day 0, inclusive),
early treatment (Days 1 to 3) and late treatment (Days 4 to 7)
periods. Where there were no significant differences in data
between these time periods, results were totalled for Days 1 to
7.
The nitrogen content of food, feces, and urine sample pools
was measured by the Dumas procedure using a Carlo Erba NA
nitrogen analyzer (Milan, Italy). An automated method was
used for urinary 3-methyihistidine (3MH) following hydrolysis
and ion-exchange resin purification [111. Serum 3MH was
measured by high performance liquid chromatography using the
method of Wassner, Schlitzer and Li [121.
Serum and urinary sodium and potassium were measured by
flame photometry, serum and urinary osmolality by freezing
point osmometry, and serum and urinary calcium and phos-
phate, and serum alkaline phosphatase, glucose, cholesterol,
and triglycerides were all measured in the Chemical Pathology
Department of the Women's and Children's Hospital, North
Adelaide. Total urinary osmolar excretion was calculated as the
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urinary osmolar concentration (mOsm/liter) x urine volume
(liter/day). Urinary protein was measured using the method of
Lowry et al [13]. Serum insulin concentration was assayed
using a Pharmacia Phadeseph radioimmunoassay kit. IGF-I
levels in the serum from each rat were measured by radioim-
munoassay following separation of the IGF-I from the IGF
binding proteins using size exclusion high performance liquid
chromatography in acidic conditions [14]. Pooled samples from
Day 7 serum were used to investigate the IGF binding protein
profiles using Western ligand blots. This was performed using 1
al of the serum pool from each group, with a pool of normal age
matched females for comparison [15]. The ligand blot was
probed with 1251-IGF-I.
Histology
After removal, the left tibia was bisected longitudinally and
one-half was placed in 10% buffered formalin, dehydrated in
increasing concentrations of alcohol, and embedded in glycoll
methyl methacrylate resin [16]. Histological sections of 5 to 10
.tm thickness were cut on a motorized microtome and mounted
unstained on glass slides. Sections were examined under a Zeiss
fluorescence microscope, and the distance between the zone of
vascular invasion and the proximal part of the calcein label
measured with an eyepiece micrometer [17] to give the longitu-
dinal growth rate over the seven-day treatment period.
Data analysis
Data are reported as mean and SEM. All statistical analyses
were performed using StatView SE for the Apple Macintosh
(Abacus Concepts, Berkeley, California, USA). Differences
between groups were tested by ANOVA, using a significance
level of 95%, followed by Fisher's protected least significant
difference post hoc test. Paired Student's t-tests were used for
comparisons between Days 0 and 7 within the same group.
Regression analysis was performed using the stepwise method
of entry of independent variables.
Results
The effect of chronic renal failure on the growth of rats in the
pilot studies is shown in Figure 1. After an initial decline in
body weight in the uremic rats immediately post-operatively,
increases in body weight were parallel in the sham and uremic
groups, with no sign of catch-up growth in the uremic animals.
After approximately four weeks, the growth rate of the uremic
animals began to decline in relation to the sham operated
animals, with a 20.4 g difference in body weight being apparent
at seven days following the second operation, 29.8 g at 28 days,
and at 50 days following surgery the mean body weight differed
by 43 g between the two groups. A significant level of uremia
was present following nephrectomy, with serum urea concen-
trations elevated almost threefold and serum creatinine ele-
vated twofold over those in the sham operated animals (Fig. 2).
These levels of serum urea and creatinine were stable from
weeks three to seven following surgery. At the same time there
was a significant decline in creatinine clearance to 0.29 0.03
mllmin/100 g body wt (N 12, mean SEM) in nephrectomized
rats compared to 0.63 0.04 mllmin/100 g body wt (N = 5) in
sham operated rats.
Administration of IGF-I and/or GH for seven days to rats
with chronic renal failure of seven weeks duration resulted in
significant growth enhancement compared with the vehicle-
treated control group (Fig. 3). The percentage weight increases
were 2.0±0.8%, 11.1 0.6%, 13.7 1.0% and 18.5 1.0%for
the vehicle, IGF-I, GH and IGF-I+GH groups, respectively.
The combination of IGF-I and GH produced greater weight
gains than either IGF-I or GH alone, with GH treatment being
more effective than IGF-I. Body length gain (nose to tail tip)
over the seven day treatment period was also significantly
increased in the IGF-I and IGF-I+GH groups compared to the
control group (9.5 1.8 and 11.1 1.6 mm vs. 3.8 2.3 mm,
respectively) with the body length gain in the GH treated
animals (7.5 2.0 mm) failing to achieve statistical significance.
The improved weight gain in the IGF-I and IGF-I+GH groups
was not associated with increased food consumption, while
mean daily food intake was increased with GH treatment (Table
1). At the same time, IGF-I and/or GH treatment resulted in
greater food conversion efficiency than in the control group
(Table 1). When the improvements in food conversion effi-
ciency over the control level are summed for the IGF-I and the
GH groups, the resultant value is very close to that measured
for the IGF-I+GH group (40.3% vs. 39.6%). This suggests that
the effects of IGF-I and GH on food conversion efficiency are
additive when the treatments are combined.
Although no significant differences in mean water intake or
urine output between the four groups were identified (Table 1),
water balance was more positive in each of the treatment
groups compared to the controls. Since water and sodium
retention are features of GH treatment [18], serum and urinary
sodium concentrations and osmolality were measured to inves-
tigate whether this increased water balance was due to sodium
retention and/or greater concentration of the urine in the groups
treated with GH and/or IGF-I. Although there were no differ-
ences in urine osmolality between the groups (Table 2), total
urinary osmolar excretion was reduced with both IGF-I and GH
treatment compared to the control group (by 15% and 10%,
respectively), with the greatest reduction occurring in the
IGF-I+GH group (27%). Urinary sodium excretion was not
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Fig. 1. Body weight changes following nephrectomy (0) or sham
operation (•) (mean SEM).
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Fig. 2. Serum urea (A) and creatinine (B) levels from 1 to 6 weeks
following nephrectomy (J) or sham operation (I) (mean SEM).
significantly affected by IGF-I and/or GH treatment (Table 2),
and there was no correlation between urinary sodium excretion
and water balance (r2 = 0.107; P > 0.05). Therefore, the
increased water retention did not appear to be due to urinary
sodium retention. While there was a significant negative rela-
tionship between urinary osmolar excretion and water balance,
the correlation was low (r2 = 0.281; P < 0.002).
The contribution of protein anabolism to the observed weight
gains was evaluated using nitrogen balance studies (Fig. 4).
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Table 1. Cumulative and mean food intake, food conversion
efficiency, water intake, and water balance during a 7 day treatment
period with vehicle, IGF-I, GH or IGF-I+GH in rats with chronic
renal failure
Vehicle IGF-1 GH IGF-I+GH
Cumulative 91.3 4.0 94.1 3.8 104.2 2.5 98.6 2.4
food
intake
g/7 day
Daily food 6.1 0.2 6.0 0.1 6.5 0.l 6.0 0.1
intake
g/100g
body wt/
day
Food 6.0 2.1 24.8 1.2" 27.5 16d 39.6 16dfg
conversion
efficiencya
gig * 100%
Water intake 15.9 1.0 14.4 0.9 16.0 1.1 13.7 1.0
mlIlOO g
body wt/
day
Urine output 11.3 0.9 9.2 1.0 10.6 1.1 8.2 1.1
ml/l00 g
body wt/
day
Water 9.9 0.6 11.8 0.4c 12.2 Ø7C 12.6 0.8C
balanceb
mi/day
a Food conversion efficiency = body wt increase(g)/food intake(g),%.N = 7due to the exclusion of one rat with a negative food conversion
efficiency
b Water balance = water intake (ml/day)—urine output (mllday)
c P < 0.05 and dP < 0.001 vs. vehicle
P < 0.05 and "P < 0.001 vs. IGF-1
g p < 0.001 vs. GH
Nitrogen intake was significantly elevated only in the GH
treated group, due to the higher food consumption in these
animals. On the other hand, urinary nitrogen excretion was
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2 3 4 5 6 Fig. 3. Body weight changes in rats with uremia of 7 weeks duration
treated for 7 days with vehicle (0), IGF-I (Lx), GH (0), and IGF-I+GH
Time weeks (U) (mean SEM). a P < 0.001 vs. vehicle; b P < 0.05 vs. IGF-I; p <0.001 vs. IGF-I; "P < 0.001 vs. GH.
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Table 2. Serum and urinary sodium, osmolality and potassium
Vehicle IGF-I OH IOF-I+GH
Serum 137.2 2.2 137.9 2.3 133.9 1.3 136.8 1.4
sodium
mmol/liter
Urinary 92.4 6.9 109.5 12.1 103.5 11.3 115.2 11.3
sodium
mmol/liter
Urinary 1.01 0.02 0.94 0.03 1.04 0.04 0.90 0.06
sodium
excretion
mmol/100
g body wt/
day
Serum 303 5 299 4 297 2 297 2
osmolality
mOsmlkg
H20
Urinary 746 53 800 88 732 85 769 69
osmolality
mOsm/kg
H20
Urinary 8.16 0.21 6.87 0.20° 7.28 0.23° 5.94 0.28°
osmolar
excretion
mOsm/100
g body wt/
day
Urinary 57.5 4.3 69.0 7.5 59.3 6.9 65.6 5.6
potassium
mmol/liter
Urinary 0.63 0.02 0.59 0.02 0.59 0.03 0.51 0.03
potassium
excretion
mmol/100
g body wtl
day
Serum is from Day 7 of the treatment period. Urinary excretion rates
are given as the mean for Days I to 7.
a P < 0.001 vs. vehicleb P < 0.01 and C P < 0.001 vs. IGF-I
d P < 0.05 and P < 0.001 vs. OH
reduced in all treatment groups compared to the controls, with
reductions in total urinary nitrogen excretion of 28% in the
IGF-I+GH group, and 14% and 10% in the IGF-I and GH
treated rats, respectively. Fecal nitrogen excretion was also
reduced with IGF-I and IGF-I+GH treatment compared to the
control, but not with GH treatment alone. This decreased total
nitrogen excretion resulted in significantly greater nitrogen
retention following IGF-I or OH treatment, with even greater
effects being observed with the combination of IGF-I+GH (Fig.
4). Enhanced protein accretion was also suggested by the
significant reduction in urinary potassium excretion with IGF-
I+OH treatment (Table 2). The relative contribution of water
balance and nitrogen retention to weight gain was evaluated
using multiple regression analysis, with weight gain as the
dependent, and nitrogen retention and water balance as the
independent, variables. Nitrogen balance was found to be the
only significant determinant of weight gain, accounting for
approximately 70% of the total variability. The relationship
between the two variables was described by the equation: body
wt gain = 31.4 (N retention) — 4.33; r2 = 0.714, F = 74.8, P <
0.0001.
To assess the possible contribution of reduced muscle protein
breakdown to the enhancement of nitrogen balance, an index of
muscle protein breakdown in each group was obtained using
urinary 3MH excretion. The 3MH excretion was 0.89 0.04,
0.96 0.06, 0.92 0.05 and 0.90 0.07 jmol/l00 g body
wt/day (mean sEM) for the two days prior to treatment, and
0.86 0.03, 0.83 0.02, 0.76 0.03 and 0.69 0.04 jimol/100
g body wt/day (mean sEM) over the seven day treatment
period for the vehicle, IGF-I, GH and IGF-I+GH groups,
respectively. While there were no significant differences in
3MH excretion between the groups before treatment, both the
OH (P < 0.05) and IGF-I+GH (P < 0.001) groups had signifi-
cantly reduced urinary 3MH excretion over the seven day
treatment period compared to the control group, with the 3MH
excretion in the IGF-I+GH group also being significantly less
than with IGF-I treatment alone (P <0.01). This suggests that
at least part of the increase in nitrogen retention with OH and
IGF-I+GH treatments resulted from decreased skeletal muscle
protein breakdown. No effect on 3MH excretion of IGF-I
treatment alone was observed. To ensure that differences in
3MH excretion were not due to changes in 3MH retention by
the kidney, concentrations of 3MH in Day 7 serum were also
measured. Serum 3MH levels were found to be similar in each
group (3.79 0.52, 3.12 0.41, 3.24 0.25 and 3.54 0.29
j.mo1Jliter for the vehicle, IGF-I, OH and IGF-I+GH groups,
respectively), suggesting that retention of 3MH did not contrib-
ute to the reduction in urinary 3MH excretion.
Serum and urinary urea and creatinine concentrations were
measured on Day 0, prior to the commencement of treatment,
and again on Day 7 (Table 3). No significant differences
between groups were found in levels of serum urea or creatinine
at either Day 0 or Day 7. There was, however, a decline in
serum urea from day 0 to 7 within the vehicle, IGF-I and
IGF-I+GH treated groups (P < 0.05, paired t-test), while levels
remained stable in the GH treated group. Conversely, in the GH
group there was a reduction in serum creatinine with time (P <
0.05, paired t-test), while serum creatinine remained unchanged
in the other groups. There were no significant changes in
creatinine clearance from Day 0 to Day 7 of treatment with any
treatment (Table 3). The apparent fall in creatinine clearance in
the IGF-I treated group was not statistically significant (P =
0.0521, paired i-test). Remnant kidney weights were not signif-
icantly different between the groups (Table 3). High levels of
proteinuria were found in this model of renal failure, but urinary
protein excretion was also unaffected by IGF-I and/or OH
treatment (Table 3).
To investigate possible changes in carbohydrate metabolism,
serum glucose and insulin levels were measured at the end of
the treatment period. No significant differences were found in
serum glucose concentrations between the groups (Table 4). In
contrast, there were significant differences in serum insulin
concentrations, with both IGF-I and IGF-I+GH treatment
resulting in a significant reduction compared with vehicle or OH
alone (Table 4). OH treatment alone did not cause a significant
increase in serum insulin concentration compared to the vehicle
group.
Increased levels of immunoreactive IGF-I in the serum
ensued following IGF-I infusion (Table 4), while no significant
difference was found in serum IGF-I levels between the vehicle
and GH treated animals. There was a significant negative
correlation between the serum IGF-I and insulin levels (r2 =
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A Nitrogen Intake Fig. 4. Nitrogen intake (A), fecal (B) and urinary (C) nitrogen excre-
tion, and nitrogen retention (0) during 2 days pretreatment and 7 days
of treatment with vehicle (, JGF-l (a), GH (iJ) or IGF-I+ GH (12)
(mean sEM). a P < 0.05 vs. vehicle; b P < 0.01 vs. vehicle; P <
0.001 vs. vehicle; d P <0.05 vs. IGF-I; a P <0.001 vs. IGF-1; P <0.05
vs. GH; g P < 0.001 vs. GH; "P < 0.05 vs. IGF-I+GH.
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0.329, P < 0.001), higher IGF-I levels being related to reduced
serum insulin. Since increased serum levels of IGF binding
proteins may contribute to reduced IGF-I bioactivity in chronic
renal failure [3], effects of treatment on IGF binding protein
profiles were investigated using Western ligand blot analysis of
pooled Day 7 serum (Fig. 5). IGF-I ligand binding was observed
in bands at 50 kDa, 43 kDa, 28 kDa and 24 kDa. Only the 24 kDa
binding protein was seen to be more intensely labeled in all the
uremic groups compared with serum pooled from age-matched
normal rats. Following IOF-I treatment, there was an apparent
increase in the intensity of the 50 kDa, 43 kDa and 28 kDa
protein bands.
Since hypercholesterolemia is a potentially damaging conse-
quence of chronic renal failure [19], we also measured serum
cholesterol levels in Day 7 serum. Higher levels of serum
cholesterol were found in the uremic animals (Table 4) com-
pared with normal age-matched rats (2.38 0.18, N = 5), but
both IGF-I and IGF-I+GH treatments resulted in significant
decreases in serum cholesterol levels compared to the vehicle
group, with no significant change following treatment with OH.
There were no significant differences in serum triglyceride
levels between the groups (Table 4).
Considerable augmentation in long bone growth with IGF-I
andlor OH treatment was found using calcein as a fluorescent
bone marker in the proximal tibial epiphyseal plate (Fig. 6). In
contrast to the control group, both IGF-I and OH treatments
caused significant increases in long bone growth, with a further
significant increase being observed in the combined treatment
group. Adding the increments in bone length of the IOF-I (83.0
mIday) and the GH (81.5 mIday) groups over that seen with
vehicle treatment (59.6 mIday) gives a sum of 104.9 mIday.
Therefore the IOF-I+GH response of 99.7 jsmlday was similar
to the predicted additive response.
Disturbances of calcium and phosphate homeostasis are
observed in chronic renal failure [20], and increased phosphate
reabsorption by the kidney has been observed with both OH
and IOF-I treatment [21]. We therefore measured calcium and
phosphate concentrations in serum on the final day of treat-
ment, and urinary calcium and phosphate in urine pooled from
Days 1 to 7 (Table 5). No differences in serum or urinary
calcium levels were found between the groups. On the other
hand, higher serum phosphate levels, in combination with
reduced urinary phosphate excretion, were observed in the
IGF-I+OH group compared to both the vehicle and IGF-I
groups. Elevated serum phosphate concentrations were found
in all groups compared with age-matched normal animals (2.19
0.15 mmollliter, N = 5). Higher alkaline phosphatase (ALP)
levels were also observed with IOF-I+GH treatment compared
to the vehicle and IOF-I groups (Table 6). A significant positive
correlation was found between longitudinal bone growth and
both serum ALP (r2 = 0.41; P < 0.001), and serum phosphate
levels (r2 = 0.225; P < 0.01).
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Table 3. Serum urea and creatinine, and creatinine clearance from Day 0 and Day 7 of the treatment period, remnant kidney weight, and
urinary protein excretion
Vehicle IGF-1 GH IGF-1+GH
Serum urea mmol/liter
Day 0 17.3 1.1 15.4 1.5 15.9 0.9 16.7 1.8
Day 7 15.4 1,la 13.0 1.3 15.3 1.3 13.8 1.4k
Serum creatinine j.unol/liter
Day 0 68.2 3.9 66.2 5.0 69.4 4.2 68.0 7.0
Day 7 65.3 2.3 63.0 3.8 63.7 2.8a 67.0 7.9
Creatinine clearance ml/minIlOO g body WI
Day 0 0.399 0.022 0.437 0.035 0.390 0.022 0.380 0.040
Day 7 0.370 0.023 0.353 0.028 0.382 0.023 0.330 0.029
Remnant kidney weight
g 1.13 0.06 1.38 0.11 1.39 0.09 1.38 0.07
g/JOO g body wi 0.52 0.03 0.59 0.04 0.58 0.03 0.55 0,03
Urinary protein excretion mg/100 g body wi/day 44.95 5.91 38.48 7.47 43.83 8.65 38.06 11.96
a P < 0.05 vs. Day 0 (paired I-test)
Table 4. Serum glucose, insulin, IGF-1, cholesterol and triglyceride
levels on Day 7 of treatment (mean SEM)
Vehicle IGF-I OH IGF-L+GH
Serum glucose 9.4 0.3 10.0 0.4 9.6 0.2 9.3 0.4
mmol/liter
Serum insulin 13.3 0.8 10.6 0.98c 15.3 0.9" 10.1
p11/mi
Serum IGF-I 924 27 1965 97 1047 46 2167 12l
nglml
Serum
cholesterol
mmoi/liter
Serum
triglycerides
mmoi/iiter
a p < 0.05 and b p < 0.01 vs. vehicleC< 0.05 vs. OH
N = 7 due to insufficient serum
To our knowledge, this is the first report published to date
comparing the anabolic effects of GH, IGF-I and a combination
of IGF-I+GH in rats with chronic renal failure. Significant
growth enhancement was found with IGF-I or OH administra-
tion alone, but the greatest growth effects were seen in the
combination IGF-I+GH treated animals. The hypothesis that
IGF-I might result in greater growth responses than OH in
uremia was not supported at the doses used, as OH treatment
gave significantly greater body weight gains than IGF-I, with no
difference in longitudinal bone growth between the two treat-
ments. Of greater potential therapeutic significance, however,
was the enhancement of somatic growth found using a combi-
nation of IGF-I+GH treatment. This growth was achieved
despite the significant growth retardation established prior to
the commencement of treatment. While we cannot say whether
increasing the dose of either IGF-I or OH alone could have
achieved the same growth results, Kupfer and co-workers, in a
study of combined IGF-I/GH administration in calorically re-
stricted normal human volunteers, have presented evidence
that higher doses of GH could not stimulate growth to the same
extent as OH plus IGF-I [10].
Other research groups have previously reported either in-
creased body weight and/or length gains in uremic rats treated
Fig. 5. Western ligand blot of pooled serum (1 pJ)from rats treated for
7 days with vehicle, IGF-1, OH and IGF-I+GH and a serum pool from
normal age-matched animals. '2I-IGF-I was used as the probe, and C14
molecular weight markers are shown in the left column (C,4).
with OH [4, 5, 22,23], or no significant changes [19, 24, 25]. The
greatest response previously reported was in the first report of
GH treatment in urernic rats by Mehis and co-workers [4] with
a 133% increase in body weight gain in OH treated rats versus
controls over 14 days (27.0 g in OH treated vs. 11.6 g), a 61%
increase in body length gain (180 mm vs. 112 mm), and a 21%
increase in longitudinal growth rate using fluorescent bone
labeling (204 jan/day vs. 169 pin/day). In comparison, we found
a 583% increase in body weight gain over seven days (39.3 g vs.
4.2 g), 97% increase in body length gain (7.5 mm vs. 3.8 mm)
and almost 37% increase in long bone growth rate (81.5 jtm/day
3.64 0.19 2.85 0.18" 3.43 0.24 2.97 0.22a
1.01 0.26 0.78 0.11 0.74 0.10 0.71 0.08
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vs. 59.6 xm/day). The rats with chronic renal failure used in this
study had a moderate degree of uremia, with serum urea
concentration elevated approximately two- to threefold, and
creatinine clearance 46% of that of sham operated rats. Mehis et
al [4] and Powell, Rosenfeld and Hintz [5] used rats with greater
elevations in serum urea levels (3.7- and 3.2-fold, respectively),
and greater reduction in creatinine clearance (33% of sham rats)
[5]. However, the rats in their experiments were studied within
four weeks of the onset of renal failure, when acute renal failure
may be superimposed on the chronic process [26]. Due to
differences not only in the experimental model, but also in the
GH treatment regimen, it is difficult to compare studies. It is
significant, however, that ours has been the first published
study in which GH therapy has been initiated following at least
seven weeks of uremia, avoiding the period of acute stress
following surgery and allowing the growth retardation to be well
established. These may have been important factors allowing
the anabolic potential of GH therapy in uremic rats to be
achieved.
Both IGF-I and GH resulted in significant increases in food
conversion efficiency, with the combination of IGF-I+GH
resulting in a 6.6-fold increase compared to the vehicle group,
which was close to the predicted additive effect. Since treat-
ment of children with chronic renal failure involves restricted
dietary management [27], more efficient utilization of food
would enhance the efficacy of any therapy in uremic children.
Although an increase in food intake in uremic rats following
human GH administration has not previously been noted [4, 5],
increased appetite has been observed in children with chronic
renal failure treated with rhGH [27], and bovine GH adminis-
tration caused a dose responsive increase in food intake in
normal female rats [28]. It is interesting to speculate whether an
increased food intake is necessary for optimal growth effects
following GH administration, but not with IGF-I.
Although we have previously demonstrated that IGF-I ther-
apy can improve nitrogen balance in mildly uremic rats [8], to
our knowledge this is the first report in which nitrogen balance
Vehicle IGF-I OH IGF-I+GH
Serum 2.58 0.03 2.54 0.04 2.56 0.01 2.60 0.07
calcium
mmol/liter
Serum 2.45 0.07 2.55 0.08 2.56 0.12 2.97 0.1l
phosphate
mmol/Iiter
Serum ALP 106 14 115 11 136 12 165 15
plliter
Urinary 6.6 0.7 6.3 1.1 8.5 1.7 6.3 1.2
calcium
excretion
i.unol/100
g body
wtlday
Urinary 342 10 314 14 328 17 267 18
phosphate
excretion
.unol/1OO
g body
wt/day
has been measured in GH treated rats with chronic renal failure.
The increases in nitrogen retention with IGF-I and/or GH
treatment were of particular interest, as protein malnutrition
may play a role in the growth retardation of chronic renal failure
[1]. Nitrogen balance was improved most significantly with
combination IGF-I+GH therapy, resulting in a 90% increase in
nitrogen retained compared to the control group. In each of the
treatment groups urinary nitrogen excretion was reduced com-
pared to the control animals, with the rats treated with IGF-I,
alone or in combination, also demonstrating reduced fecal
nitrogen excretion. Reductions in fecal nitrogen excretion have
previously been reported following IGF-I treatment in intesti-
nally resected rats [29] and may be a result of greater absorptive
capacity due to a selective effect of IGF-I treatment on gut
growth [8, 29]. Improved nitrogen absorption by the gut may be
one of the factors contributing to the increased food conversion
efficiency observed in our study.
Increased protein accretion was also suggested by a signifi-
cant reduction in urinary potassium excretion in the combined
treatment group, a result which concurs with data of Kupfer et
al [10], in which IGF-I+GH therapy in human volunteers with
calorie restriction resulted in reduced urinary potassium excre-
tion. Potassium balance is a good index of protein accrual in the
muscle and connective tissue compartments of the body as 83%
of the total potassium is present in these compartments [30].
Although in our present study the rats were significantly
growth retarded, they were not in a state of net catabolism, as
evidenced by the positive nitrogen balance in the vehicle
treated group. Nevertheless, GH and IGF-I+GH treatment
resulted in reduced protein degradation, as indicated by the fall
in urinary 3-methylhistidine (3MH) excretion. Urinary 3MH
excretion is a valid index of muscle protein breakdown, since
3MH is derived exclusively from actin and myosin, found
principally in muscle tissue, and is excreted quantitatively in rat
urine following actin and myosin catabolism [31].
120-
100-
80-
a
b
C
Table S. Serum and urinary calcium and phosphate, and serum
alkaline phosphatase (ALP) levels (mean SEM)
40-
20 -
0.
Fig. 6. Longitudinal growth rate in the proximal tibia using calcein as
a fluorescent bone marker in uremic rats treated for 7 days with vehicle
(U), IGF-I (a), GH (El), and IGF-I+GH (i) (mean SEM,}. a O
0.001 vs. vehicle; bp < 0.01 vs. IGF-I; C p < 0.01 vs. OH.
a P < 0.01 and b P < 0.001 vs. vehicle
P < 0.01 vs. IGF-I
d p < 0.01 vs. GH
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The major aim of rhGH therapy in children with chronic renal
failure is to increase their final adult height. Therefore, the
additive effects we observed with IGF-I plus GH in promoting
long bone growth were highly significant. Treatment of uremic
rats with rhGH has previously been shown to increase longitu-
dinal bone growth by 20% over those treated with vehicle alone
[4]. The rates of tibia! longitudinal growth in untreated uremic
rats measured in our study were low compared to those found
by Mehis et a! (59.6 pm/day vs. 169 tm/day) [4], due either to
the fact that the rats in our study were older when treatment
commenced, or to the longer duration of uremia with more
substantial growth retardation. In this context, the 67% aug-
mentation of bone growth observed in the IGF-I+GH treated
group is even more impressive since the initial growth rate was
so low.
In chronic renal failure, disturbances in calcium and phos-
phate metabolism due to changes in vitamin D metabolism and
secondary hyperparathyroidism result in renal osteodystrophy
[1]. Indeed, serum phosphate levels were elevated in all of the
uremic animals in the present study. Increased serum phos-
phate levels have not previously been reported in uremic rats
[4, 32], possibly because of the shorter duration of renal failure
than in our study. GH indirectly stimulates renal reabsorption
of phosphate via IGF-I, and Caverzasio, Montessuit and Bon-
jour have suggested IGF-I as the key regulator of renal phos-
phate transport providing the increased phosphate necessary
for growth [211. However, in the present study, urinary phos-
phate reabsorption and serum phosphate levels were signifi-
cantly increased only with combined IGF-I+GH adminstration.
Mehls and co-workers also failed to see any increase in serum
phosphate with GH alone [4], and rhGH treatment in uremic
children results in no alteration in serum phosphate levels [27].
The increase in phosphate retention that occurred with IGF-
I+GH administration might be related to the greater growth
response in this group. Similarly, the elevated serum levels of
alkaline phosphatase with combined treatment, and their cor-
relation with growth rate, relate to the positive effect of
combined treatment on bone growth. Serum alkaline phos-
phatase has been reported as reflecting osteoblast activity in
studies of GH treatment in children with chronic renal failure
[6, 27].
The anabolic effects of GH may be direct, or mediated
indirectly via IGF-I [2]. Despite the growth responses seen with
rhGH treatment, no increase in serum IGF-I levels was found,
while serum IGF-I rose approximately twofold following IGF-I
infusion compared to the control animals. Failure of GH to
increase serum IGF-I concentration in uremic rats has also been
reported in other studies [4, 5]. This suggests a species differ-
ence in the response to GH, since uremic children treated with
rhGH do have significantly elevated serum IGF-I levels [33],
and IGF-I+GH therapy in normal humans caused an increase in
serum IGF-I levels compared to IGF-I alone [10]. The fact that
GH did not increase IGF-I levels in uremic rats, despite having
pronounced growth effects in these animals, supports a direct
effect of GH therapy on growth. On the other hand, GH may
have acted indirectly via increased local tissue IGF-I produc-
tion, with the serum IGF-I levels remaining unchanged.
The combination of IGF-I and OH resulted in dramatic
responses, and it is interesting to speculate on possible reasons
for the enhanced efficacy of combined treatment. The greater
anabolic effect may be due, in part, to IGF-I and GH having
different effects which, in combination, may result in comple-
mentary results greater than if either peptide was used alone.
For example, the effects of IGF-I and GH on protein balance
may not be identical. IGF-I treatment alone did not significantly
alter 3MH excretion, while GH treatment resulted in a signifi-
cant reduction, suggesting reduced muscle protein breakdown
in the GH treated group. On the other hand, IGF-I treatment
resulted in reduced fecal nitrogen excretion, suggesting im-
proved nitrogen absorption from the gut, whereas no change
resulted with GH treatment alone. The additive longitudinal
bone growth response to IGF-I+GH may also be due to a
combination of different effects. Prechondrocytes appear to be
most responsive to the effects of GH, while the committed
progenitor cells are more responsive to IGF-I [34] therefore
combination treatment may result in both an increase in stem
cell number, and an increased number of stem cells becoming
committed to enter the growth plate as functional chondro-
cytes.
Apart from the anabolic effects, combination IGF-I+GH
therapy may offer advantages over treatment with GH or IGF-I
alone in terms of metabolic effects. One of the rationales for
combination IGF-I+GH therapy was to reduce the hyperinsu-
linemia which could result from rhGH administration. Although
we did not find increased serum insulin levels following GH
treatment, there was a significant decrease in serum insulin
levels following IGF-I administration, both alone and combined
with GH. Kupfer et a! [10], in human volunteers, also found a
decrease in serum insulin levels with IGF-I+GH, although the
decrease was less than with IGF-I alone. IGF-I has a direct
effect to reduce insulin secretion from the pancreas [9], and its
role in reducing insulin levels was reinforced in this study by the
negative correlation found between serum IGF-I and insulin
levels. In uremic children treated with rhGH, euglycemia is
maintained at the expense of hyperinsulinemia [61. Potential
problems with insulin resistance include hypertension, diabetes
and dyslipidemia, all of which may predispose to atherogenic
diseases [35]. By administering IOF-I with OH the potential
problems arising from insulin resistance may be avoided. An
additional benefit of coadministration of IGF-I+GH may be
reduction of hypercholesteremia. All the uremic rats in this
study had elevated serum cholesterol levels, with a significant
reduction in serum cholesterol following IGF-I or IGF-I+GH
administration. Treatment with GH alone did not result in a
significant change in serum cholesterol levels, a result which
confirms a previous report by Santos et al [36]. To our knowl-
edge, this is the first report of changes in serum cholesterol
levels in rats following IGF-I administration. There were no
significant differences in the serum triglyceride levels between
any groups in this study, suggesting there were no changes in
either fat absorption in the gut, or triglyceride synthesis in the
liver. While it is difficult to speculate on the causes for the
reduced serum cholesterol levels in this study as the full lipid
profile was not measured, further studies are warranted to
elucidate the mechanisms involved.
One of the major concerns with any form of therapy in
children with chronic renal failure is that no deleterious effects
on residual kidney function should occur. Since elevated GH
and IGF-I levels are associated with increased GFR in humans
and rats [37, 38] and hyperfiltration has been proposed to
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contribute to the progression of renal failure [39], there is the
possibility that long-term treatment with GH and/or IGF-I
might be deleterious to the kidney. Data on the possible effects
of IGF-I or GH on GFR in conditions of reduced renal func-
tional mass are conflicting, with some studies showing no effect
of hGH in children or in rats [25, 40], while a recent study using
IGF-I treatment in adult patients with chronic renal failure
showed a significant increase in GFR [41]. It is important to
note that, to date, no effects on renal function have been found
in children with chronic renal failure treated with GH [6].
Overexpression of GH in transgenic mice does, however, result
in glomerulosclerosis, which does not appear to occur when
only IGF-I levels are elevated [42]. We did not observe any
significant change in creatinine clearance following seven days
of treatment with IGF-I and/or GH, however, the treatment
period was too short to reach any conclusions on possible
long-term effects.
We have demonstrated that, although rhIGF-I treatment does
not appear to offer any advantages over rhGH in terms of the
growth response in uremic rats, there is therapeutic potential
for combined IGF-I+GH treatment. Combination therapy re-
sulted in additive increases in longitudinal bone growth and
food conversion efficiency, and caused significantly greater
body weight gains and nitrogen retention than IGF-I or GH
alone. A combination of IGF-I+GH also had the advantages of
reducing serum insulin and cholesterol levels. Therapeutic
potential exists for lower combined doses of IGF-I and GH to
produce the same growth effects as higher doses of either
peptide alone, with the possibility of a reduced risk of long-term
side effects.
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